diabetestalk.net

Drug For Type 2 Diabetes Provides Significant Benefits To Type 1 Diabetic Patients

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

A majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes and Endocrinology. The results are being presented today by the University at Buffalo researcher who led the study at the annual meeting of the European Association for the Study of Diabetes in Lisbon.
Called DEPICT-1, which stands for Dapagliflozin in Patients with Inadequately Controlled Type 1 diabetes, the 24-week study was the first global multicenter investigation of dapagliflozin to test its efficacy and safety in Type 1 diabetes. The double-blind, randomized, three-arm, phase 3 multicenter study was conducted at 143 sites in 17 countries, including the U.S. It was funded by AstraZeneca and Bristol-Myers Squibb, the companies that partnered to develop dapagliflozin.
Participants were 833 patients aged 18-75 who had inadequately controlled blood sugars with a mean baseline hemoglobin A1C (HbA1c)—a measure of sugar in the blood—level of 8.53. A1C levels for Type 1 diabetics are considered optimal when they are under seven.
Adjunct to insulin
The results demonstrate that when this drug, a sodium glucose cotransporter-2 inhibitor (SGLT-2) was administered as an adjunct therapy in addition to the insulin that patients with Type 1 diabetes need to survive, it significantly improved outcomes.
"Our paper provides the initial signal that dapagliflozin is safe and effective in patients with Type 1 diabetes and is a promising adjunct treatment to insulin t Continue reading

Rate this article
Total 1 ratings
Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis

Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis


Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis
Although the regular consumption of resveratrol has been known to improve glucose homeostasis and reverse insulin resistance in type 2 diabetes mellitus (T2DM), the reported results are inconsistent. Thus, we aimed to assess the effects of resveratrol on glycemic control and insulin sensitivity among patients with T2DM. We searched for relevant articles published until June 2017 on PubMed-Medline, Embase, Cochrane Library, and Web of Science. Randomized controlled trials in T2DM patients administered with resveratrol as intervention were included. After study selection, quality assessment and data extraction were performed independently by two authors, and STATA and RevMan software were used for statistical analysis. Nine randomized controlled trials involving 283 participants were included. Meta-analysis showed that resveratrol significantly improved the fasting plasma glucose ( 0.29 mmol/l, 95% CI: 0.51, 0.06, p < 0.01) and insulin levels (0.64 U/mL, 95% CI: 0.95, 0.32, p < 0.0001). The drug also reduced homeostasis model assessment of insulin resistance (HOMA-IR) index, systolic blood pressure, and diastolic blood pressure among participants with T2DM. The changes in hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were negligible. Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus 100 mg/d revealed a significant difference in fasting plasma gluc Continue reading

Start a 'SUGAR LIPS' Log to Help You Manage Your Diabetes - Divabetic

Start a 'SUGAR LIPS' Log to Help You Manage Your Diabetes - Divabetic


Diamonds may be a girls best friend, but lipstick runs a close second. Why not incorporate your diabetes self-care into your daily beauty routine?
I truly believe that you have to love yourself enough to want to improve your diabetes health. Since 90% of women feel that wearinglipstickmakes them feel better about themselves, why not reward yourself before you check your blood sugars by adding some color to your lips? The little boost of confidence you gain from your favorite shade can help you to cope with those unexpected readings too.
15 MINUTE Beauty s Best Splurge Red Lipsticks:Macs Ruby Woo is one their best selling reds for a good reason! Its a classic bright red that works for almost everyone. BUY IT
If youve struggled in the past with adding your diabetes self-care into your daily routine then a SUGAR LIPS log just might be the answer. Experts agree that linking my new habit with a current behavior make it much easier to change. No need to be motivated. No need to remember.
One good example of this concept is creating a new habit of flossing by always doing it after brushing your teeth. The act of brushing your teeth is something that you already do and that acts as the reminder to do your new behavior. READ MORE
When you stop and think that most women apply theirlipstick4 or more times in one day the resulting SUGAR LIPS log data could prove to extremely beneficial to you and your doctor. If you try it, I bet you will both be smiling! And guess what? A new tube oflipstickis a healthy way to reward yourself for lowering your A1C.
15 MINUTE Beauty s Best Splu Continue reading

Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle Libre, Now Available To Medicare Patients - Jan 4, 2018

Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle Libre, Now Available To Medicare Patients - Jan 4, 2018


Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle Libre, Now Available To Medicare Patients
- CMS reimbursement provides opportunity for Medicare patients who meet eligibility criteria to access FreeStyle Libre System
- FreeStyle Libre System can replace traditional blood glucose monitoring, eliminating the need for routine fingersticks(1) or any user calibration
ABBOTT PARK, Ill., Jan. 4, 2018 / PRNewswire / --Abbott (NYSE: ABT) today announced that the FreeStyle Libre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). Coverage includes all Medicare patients with diabetes who use insulin and who meet the eligibility criteria2.
The factory-calibrated FreeStyle Libre system is the only CGM system recognized by Medicare that requires no user calibration whatsoever (either by fingerstick or manual data entry). The system also does not require the need for routine fingersticks1. The high accuracy of the FreeStyle Libre system allows for patients to dose insulin based on the results1.
"At Abbott, we are continuously challenging ourselves to ensure our innovative technology is accessible to the majority of people who need it," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "CMS's recognition of this revolutionary health technology, which removes the need for any user calibration, is ultimately going to empower Medicare beneficiaries with d Continue reading

Unlocking the universal language of emojis in radical bid to help illiterate type 2 diabetes sufferers

Unlocking the universal language of emojis in radical bid to help illiterate type 2 diabetes sufferers

Like belief in imminent Rapture, type 2 diabetes finds its biggest constituency among the poor, the poorly educated and the disadvantaged.
"In the developed world, diabetes is far more prevalent in low-income, migrant and ethnic minority groups, regardless of which country in the world you go to," says Timothy Skinner, professor of psychology at Charles Darwin University in the Northern Territory capital.
"Why that's so is an interesting conversation. It's probably a combination of things such as the costs of living a more healthy life; the costs of food and nutrition. But also we know that depression is a risk factor – the daily burdens of lower socioeconomic groups are a problem."
Globally, according to the World Health Organisation, those burdens have produced more than 422 million cases of type 2 diabetes, causing 3.7 million deaths a year. In Australia, about 1.7 million people are affected.
SHARE
Share on Facebook SHARE
Share on Twitter TWEET
Link
The linkage of diabetes with people whose choices are severely constrained by history, language and income creates a whole raft of problems – as if having a progressive condition that can lead to blindness, amputation and kidney failure was not enough.
Prime among these are difficulties understanding written material about the subject – especially if that material isn't available in an appropriate language – and being unable to grasp the helpful, but not easy, advice offered by doctors.
Indeed, the critical relationship between patient and physician often becomes strained, as each participant fails to understand the Continue reading

No more pages to load

Popular Articles

Related Articles